FDA slams In­cyte's PD-1 over sin­gle-arm study, low re­sponse and tri­al deaths

The ever-grow­ing PD-1 land­scape could see a new en­trant as an In­cyte pro­gram is slat­ed for an FDA de­ci­sion next month. But first, the biotech will have to get through an ad­comm Thurs­day, and brief­ing doc­u­ments from the agency ap­pear to cast doubt over how ef­fec­tive the can­di­date re­al­ly is.

Atop the is­sues is whether or not the com­pound reti­fan­limab has enough da­ta for an ac­cel­er­at­ed ap­proval, af­ter In­cyte treat­ed sec­ond-line pa­tients with squa­mous car­ci­no­ma of the anal canal in a sin­gle-arm tri­al. In­cyte’s study showed an over­all re­sponse rate of just 14% among 94 pa­tients, and the FDA says they’re un­sure whether this would cor­re­spond to a clin­i­cal ben­e­fit in a larg­er, place­bo-con­trolled tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA